Heather Han

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Triple-negative breast cancer molecular subtyping and treatment progress

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Cancer statistics, 2020

Immune Checkpoint Blockade for Breast Cancer

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Checkpoint inhibitors in breast cancer – Current status

Deep learning in histopathology: the path to the clinic

Understanding the Intersections between Metabolism and Cancer Biology

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

Implications of the tumor immune microenvironment for staging and therapeutics

Immune checkpoint inhibitors: recent progress and potential biomarkers

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Breast Cancer Statistics, 2022

Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors.